Free Trial

Cerity Partners LLC Raises Stock Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

Takeda Pharmaceutical logo with Medical background

Cerity Partners LLC increased its holdings in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 81.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 159,285 shares of the company's stock after purchasing an additional 71,634 shares during the quarter. Cerity Partners LLC's holdings in Takeda Pharmaceutical were worth $2,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of TAK. FNY Investment Advisers LLC bought a new stake in shares of Takeda Pharmaceutical in the first quarter worth about $37,000. Farther Finance Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Takeda Pharmaceutical in the fourth quarter worth about $52,000. Fifth Third Bancorp grew its stake in shares of Takeda Pharmaceutical by 85.5% in the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after purchasing an additional 2,411 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Takeda Pharmaceutical in the fourth quarter worth about $94,000. 9.17% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Read Our Latest Analysis on TAK

Takeda Pharmaceutical Trading Up 1.3%

Shares of NYSE TAK traded up $0.20 during trading hours on Wednesday, hitting $14.75. The company's stock had a trading volume of 4,701,934 shares, compared to its average volume of 2,040,444. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. The stock has a market cap of $46.92 billion, a price-to-earnings ratio of 67.03 and a beta of 0.23. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.53. The business has a 50-day simple moving average of $14.87 and a 200-day simple moving average of $14.46.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). The firm had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. On average, analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

(Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Further Reading

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Should You Invest $1,000 in Takeda Pharmaceutical Right Now?

Before you consider Takeda Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.

While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines